Researchers Identify Three New Biomarkers for IgA Nephropathy

A new study reveals key complement-related genes that could improve diagnostic accuracy for the chronic kidney condition.

Updated on Oct. 23, 2026 in Biotech

Isometric editorial illustration showing a stylized, geometric DNA strand, representing molecular genetic research for kidney disease.
Researchers have identified three gene biomarkers, A2M, C3AR1, and SERPINA1, that improve diagnostic accuracy for IgA nephropathy to 95.9 percent. AI Illustration. Upload story photo >

Scientists have identified three specific gene biomarkers for immunoglobulin A (IgA) nephropathy. A machine-learning classifier using these markers achieved an external validation accuracy of 0.959.

Why it matters

Complement-related molecular markers for IgA nephropathy remain incompletely defined, hindering precise diagnostic efforts. These new candidates offer a pathway toward better identifying the disease.

The study utilized an ANN classifier that reached an external-validation AUC of 0.959, following training on dataset GSE93798. Researchers also confirmed higher expression of A2M and C3AR1 in IgAN tissues compared to healthy donor controls.

The details

The research team integrated bulk transcriptomic datasets and single-cell RNA-seq data to isolate 25 differentially expressed complement-related genes. Through algorithms like LASSO, SVM-RFE, and Boruta, the study narrowed these down to A2M, C3AR1, and SERPINA1 as the most reliable markers.

Timeline

  1. The research findings were officially published on October 23, 2026.

The Big Picture

This discovery shifts the trajectory of renal diagnostics by moving toward molecular-based classification systems. It marks a departure from traditional, solely morphology-based diagnostic standards for kidney disease.

These findings provide a foundation for future diagnostic tools that could lead to faster and more accurate identification of IgA nephropathy. Patients may eventually benefit from refined testing methods that reduce the time required to confirm a diagnosis.

The takeaway

The successful identification of these biomarkers represents a significant technical step toward more precise molecular screening for kidney conditions. Future clinical applications depend on the ongoing validation of these markers across diverse patient populations.

Further reading

Explore more advancements in Biotech to see how molecular research is reshaping medical diagnostics.

More information

Read the complete Peer-reviewed research article for a detailed technical breakdown of the gene analysis.

Source note: This article includes information reported by Nature.